Cannabis Science Pioneer Tikun Olam Expands Partnership with MariMed to Bring Branded Cannabis Products to More U.S. MMJ States

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Cannabis Science Pioneer Tikun Olam Expands Partnership with MariMed to Bring Branded Cannabis Products to More U.S. MMJ States

Deal Combines Tikun Products & Unparalleled Research with MariMed's Cultivation & Distribution Networks

PR Newswire

NEWTON, Mass. and NEW YORK, Sept. 19, 2017 /PRNewswire/ -- Tikun Olam, the world pioneer in cannabis research, and MariMed Inc. (OTCQB:MRMD), a preeminent management company in the U.S. medical cannabis industry, announced an expansion of their licensing agreement for Tikun Olam products to be grown, manufactured and sold through MariMed's network of managed and affiliated licensed facilities throughout the United States.

Tikun (PRNewsfoto/T.O. Global LLC)

This new agreement brings Tikun Olam's premium cannabis products, years of proprietary, peer-reviewed scientific research and unprecedented clinical data collection to four additional MMJ-legal U.S. states, its most expansive agreement to date. Tikun Olam and MariMed's relationship began in 2015 with a pilot program in Delaware and marked the first time that U.S. patients had access to the world's only cannabis strains proven to deliver symptomatic relief for specific conditions including cancer, PTSD, epilepsy, Crohn's Disease/Colitis, chronic pain and neuropathy to name a few.

"After the great success of our program in Delaware, MariMed is excited to bring Tikun™ to our expanding national network of legal cannabis production and dispensary facilities," says Robert Fireman, CEO of MariMed Inc. "Tikun Olam's empirical data on clinical effectiveness is unsurpassed, and we look forward to educating healthcare professionals and offering Tikun's products to tens of thousands of new patients nationwide."

MariMed will introduce Tikun's exclusive strains and products in state-of-the-art, regulatory compliant and fully operational cultivation and medical marijuana dispensaries in Rhode Island, Maryland, Massachusetts and Illinois in 2018. Tikun products will be available in flower, vape cartridges, topicals, tinctures and edibles utilizing at least six Tikun™ branded strains, including its world-renowned Avidekel™ high-CBD strain.  In addition to Delaware, Tikun™ products have launched in Nevada (March 2017) and are expected to launch Washington (November 2017).

"Tikun Olam is delighted to expand our relationship with MariMed," says Tikun CEO Bernard Sucher.  "MariMed utilizes the "best practices" and standards for cultivation and production and their qualified distribution channels allow us to bring our proven wellness products to more U.S. patients than ever before."

About Tikun Olam
Tikun Olam ("repair the world" in Hebrew) is the world's leading cannabis brand and globally recognized as the pioneer of modern medical cannabis. Operating as a commercial venture for over 10 years, Tikun Olam's products have been used since 2010 in ongoing clinical trials in Israel's regulated medical cannabis market, treating over 10,000 patients for a variety of symptoms of medical conditions such as Cancer, PTSD, AIDS, epilepsy, Crohn's Disease/Colitis, multiple sclerosis, cerebral palsy, chronic pain and neuropathy. Through this access to patients, medical personnel and data collection, Tikun Olam has developed multiple proprietary strains, including the first-ever, high-CBD, "high-less" strain Avidekel™, its popular high-THC strain Alaska™, and its "one-to-one" CBD/THC strain Midnight™. Tikun Olam's U.S. operations, established in 2015 as T.O. Global LLC, is a joint venture with Tikun Olam Ltd. (Israel). Tikun Olam also operates similar partnerships in Canada (TSX: LEAF), Australia, Germany and South Africa, all in support of its global mission to educate the traditional medical community and its patients on the applications of cannabis as a scientifically proven wellness product. Visit www.tikunolamusa.com, and follow us on Facebook, Twitter, and Instagram.

About MariMed
MariMed is an industry leading professional management company in the emerging cannabis industry. Marimed designs, develops, operates, funds, and optimizes medical cannabis cultivation, production, and dispensary facilities. MariMed's team has developed state-of-the-art, regulatory-compliant legal cannabis facilities in multiple states. These facilities are models of excellence in horticultural principles, cannabis production, product development, and dispensary operations. MariMed is on the forefront of precision-dosed cannabis medicine for the treatment of specific medical conditions. MariMed's branded products, such as Kalm Fusion™, are being licensed and distributed in legal cannabis states across the country. For additional information, visit www.MarimedAdvisors.com.

Forward-Looking Statements
This release contains certain forward-looking statements and information relating to MariMed Inc. (the "Company") that are based on the current beliefs of the Company's management, as well as assumptions made by, and information currently available to, the Company. Such statements reflect the current views of the Company with respect to future events and are subject to certain assumptions, including those described in this release. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as "should," "could," "anticipate," "believe," "intend," "plan," "might," "potentially" or "expect." The Company does not intend to update these forward-looking statements.

CONTACTS:




Tikun Olam Holding LLC/ Tikun™           

MariMed            

Chief Marketing Officer            

Business Development         

Stephan Gardner               

Jon Levine, CFO, MariMed    

[email protected]             

[email protected]        


844-244-0200



Media Relations

Investor Relations

Gia Moron, GVM Communications

Ed McGregor/Jody Burfening, LHA  

[email protected]

[email protected]  

Tracey Henry / Brenda Loughery, Type A Media

212-838-3777  

[email protected]; [email protected]



Media Relations  


Julie Shepherd, Accentuate PR  


[email protected]
847-275-3643



 

View original content with multimedia:http://www.prnewswire.com/news-releases/cannabis-science-pioneer-tikun-olam-expands-partnership-with-marimed-to-bring-branded-cannabis-products-to-more-us-mmj-states-300521768.html

SOURCE Tikun Olam

Copyright CNW Group 2017

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).